MTOR and cancer: However, the mTOR inhibitor, everolimus, showed no therapeutic benefit in unselected MPM patients.7 As mTORC1 inhibitors often lead to a feedback activation of PI3K activation in cancers,8, 9 we postulated that dual PI3K–mTOR inhibitors may yield greater therapeutic benefit.